CY1110351T1 - Στερεες φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που λαμβανονται με θερμοδιαμορφωση - Google Patents

Στερεες φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που λαμβανονται με θερμοδιαμορφωση

Info

Publication number
CY1110351T1
CY1110351T1 CY20081100615T CY081100615T CY1110351T1 CY 1110351 T1 CY1110351 T1 CY 1110351T1 CY 20081100615 T CY20081100615 T CY 20081100615T CY 081100615 T CY081100615 T CY 081100615T CY 1110351 T1 CY1110351 T1 CY 1110351T1
Authority
CY
Cyprus
Prior art keywords
controlled release
temperature
pharmaceutical compositions
solid pharmaceutical
release taken
Prior art date
Application number
CY20081100615T
Other languages
English (en)
Inventor
Patrick Wuthrich
Hervé Rolland
Gilles Briault
Gérald Pichon
François Tharrault
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9547360&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1110351(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of CY1110351T1 publication Critical patent/CY1110351T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια νέα στερεά φαρμακευτική σύνθεση ελεγχόμενης απελευθέρωσης, και λαμβανόμενη με θερμοδιαμόρφωση εν θερμώ ενός μίγματος με βάση πολυμερή που ανήκουν στην οικογένεια των πολυμεθακρυλικών παραγώγων, και φαρμακευτικού (-κών) δραστικού (-κών) συστατικού (-κών).
CY20081100615T 1999-06-28 2008-06-10 Στερεες φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που λαμβανονται με θερμοδιαμορφωση CY1110351T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9908210A FR2795326B1 (fr) 1999-06-28 1999-06-28 Composition pharmaceutique solide thermoformable a liberation controlee
EP00401825A EP1064935B2 (fr) 1999-06-28 2000-06-27 Compositions pharmaceutiques solides à libération prologée obtenues par thermoformage

Publications (1)

Publication Number Publication Date
CY1110351T1 true CY1110351T1 (el) 2015-04-29

Family

ID=9547360

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100615T CY1110351T1 (el) 1999-06-28 2008-06-10 Στερεες φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που λαμβανονται με θερμοδιαμορφωση

Country Status (23)

Country Link
US (1) US6319520B1 (el)
EP (1) EP1064935B2 (el)
JP (2) JP2001031591A (el)
KR (1) KR100554899B1 (el)
CN (1) CN1174744C (el)
AT (1) ATE395045T1 (el)
AU (1) AU765885B2 (el)
BR (1) BR0002880A (el)
CA (1) CA2312545C (el)
CY (1) CY1110351T1 (el)
DE (1) DE60038848D1 (el)
DK (1) DK1064935T4 (el)
EA (1) EA003751B1 (el)
ES (1) ES2307489T5 (el)
FR (1) FR2795326B1 (el)
HK (1) HK1033435A1 (el)
HU (1) HU229342B1 (el)
NO (1) NO331449B1 (el)
NZ (1) NZ505431A (el)
PL (1) PL202494B1 (el)
PT (1) PT1064935E (el)
SI (1) SI1064935T2 (el)
ZA (1) ZA200003245B (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510311A (en) * 1998-09-08 2003-08-29 Smithkline Beecham Corp Lipstatin derivative - soluble fiber tablets
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
FR2818550B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controle de perindopril
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US7247313B2 (en) * 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US6656216B1 (en) 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
GB0117619D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
US7622146B2 (en) * 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US7169178B1 (en) 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
JP5501553B2 (ja) 2003-04-21 2014-05-21 ユーロ−セルティーク エス．エイ． 同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
RS51934B (en) 2003-08-08 2012-02-29 Biovail Laboratories International Srl. BUPROPION HYDROCHLORIDE TABLE WITH MODIFIED RELEASE
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
WO2005097075A2 (en) 2004-03-30 2005-10-20 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
WO2006004719A2 (en) 2004-06-25 2006-01-12 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
CA2641351C (en) * 2006-02-03 2014-05-06 Christian Meier Pharmaceutical compositions containing mixtures of polymers and active agents poorly soluble in water
EP2001350A4 (en) * 2006-03-20 2013-04-17 Teva Womens Health Inc FLEXIBLE COMPRESSED INTRAVAGINAL RINGS, METHOD FOR THEIR PRODUCTION AND USE AND DEVICE FOR THEIR PRODUCTION
US8003156B2 (en) 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
EP2150525A1 (en) * 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
EP3045043B1 (en) 2009-02-26 2020-04-29 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
EP2550863A1 (de) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis
WO2013030267A1 (en) * 2011-08-30 2013-03-07 Universiteit Gent Multi-layered release formulation
CA2877410A1 (en) 2012-07-16 2014-01-23 Ratiopharm Gmbh Complex of agomelatine and cyclodextrin
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
KR101659983B1 (ko) 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EP2810656B1 (en) 2013-06-06 2017-08-02 Zentiva, a.s. Agomelatine formulations comprising agomelatine in the form of co-crystals
CN103724415B (zh) * 2013-12-31 2015-05-27 中山大学 斜带石斑鱼性别调控基因Rspo1及其制备方法和应用
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
FR3070619A1 (fr) 2017-09-01 2019-03-08 Ab7 Innovation Piece moulee monolithique en matrice multiple pour la diffusion d’actifs et son procede d’obtention
ES2938608T3 (es) 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
TW201929851A (zh) * 2017-11-02 2019-08-01 日商石原產業股份有限公司 緩釋性醫藥組成物
KR101856911B1 (ko) * 2017-12-13 2018-05-10 동국대학교 산학협력단 펠루비프로펜의 서방성 고체분산체 제제 및 이의 제조방법
CN109985025B (zh) * 2017-12-29 2023-01-13 沈阳药科大学 具有pH触发释药特征的眼部缓释给药***

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
DE4138513A1 (de) † 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JPH11514979A (ja) † 1995-09-07 1999-12-21 フイズ テクノロジーズ リミテッド 実質的に非溶解性の生体作用薬剤をバイオ・アベイラブルにするシステム
DE19539362A1 (de) † 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19728516C2 (de) * 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol
FR2766088B1 (fr) * 1997-07-17 2001-01-05 Dow Corning Sa Dispositifs a liberation controlee d'un agent pharmaceutique, leur fabrication par co-extrusion et article intermediaire
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee

Also Published As

Publication number Publication date
DK1064935T4 (da) 2011-09-26
PL341042A1 (en) 2001-01-02
HU229342B1 (en) 2013-11-28
US6319520B1 (en) 2001-11-20
BR0002880A (pt) 2001-01-30
JP2006077033A (ja) 2006-03-23
DE60038848D1 (de) 2008-06-26
NO20003349D0 (no) 2000-06-27
AU4273400A (en) 2001-01-04
AU765885B2 (en) 2003-10-02
EP1064935A1 (fr) 2001-01-03
EA200000584A2 (ru) 2000-12-25
EP1064935B2 (fr) 2011-06-08
SI1064935T1 (sl) 2008-08-31
FR2795326A1 (fr) 2000-12-29
NO20003349L (no) 2000-12-29
ATE395045T1 (de) 2008-05-15
HU0002469D0 (en) 2000-08-28
CN1174744C (zh) 2004-11-10
EA003751B1 (ru) 2003-08-28
NO331449B1 (no) 2012-01-02
PL202494B1 (pl) 2009-06-30
ZA200003245B (en) 2001-01-17
HUP0002469A3 (en) 2008-04-28
HUP0002469A2 (en) 2002-06-29
CA2312545C (fr) 2006-09-12
ES2307489T5 (es) 2011-11-07
DK1064935T3 (da) 2008-08-25
CA2312545A1 (fr) 2000-12-28
EP1064935B1 (fr) 2008-05-14
NZ505431A (en) 2002-12-20
PT1064935E (pt) 2008-07-03
KR100554899B1 (ko) 2006-02-24
EA200000584A3 (ru) 2001-04-23
HK1033435A1 (en) 2001-08-31
FR2795326B1 (fr) 2001-08-31
KR20010049643A (ko) 2001-06-15
ES2307489T3 (es) 2008-12-01
JP2001031591A (ja) 2001-02-06
SI1064935T2 (sl) 2011-12-30
CN1285188A (zh) 2001-02-28

Similar Documents

Publication Publication Date Title
CY1110351T1 (el) Στερεες φαρμακευτικες συνθεσεις ελεγχομενης απελευθερωσης που λαμβανονται με θερμοδιαμορφωση
CY1106390T1 (el) Στepεα θepμοδιαμορφωσιμη φαρμακευτικη συνθεση για την ελεγχομενη απελευθερωση της ιβαβραδινης
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
CY1105268T1 (el) Αντι-ιικες στepεες διασπορες
CY1110558T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
BR0207640A (pt) Composição farmacêutica oral de cefpodoxima proxetil
CY1105235T1 (el) Συνθεσεις λασοφοξιφενης
CY1109711T1 (el) Νεα κρυσταλλικη μορφη υδροχλωριουχου λερκανιδιπινης και διαδικασιες για την παρασκευη τους
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
CY1108770T1 (el) Νεα παραγωγα του ινδολιου και χρηση τους ως φαρμακων
HK1030218A1 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same.
DK0971717T3 (da) Cytotoksiske aminosukker- og relaterede sukkerderivater af indolopyrrolocarbazoler
NO974321D0 (no) Nodulisporsyrederivater
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
CY1105798T1 (el) Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
ATE266400T1 (de) Heterocyclyl sulphonamid derivate
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
DE60039631D1 (de) Cyclopentyl sulfonamid derivaten
CY1105463T1 (el) Ελεγχομενη χορηγηση αντικαταθλιπτικων
HN1998000045A (es) Composiciones farmaceuticas